Enright Patrick G's Form 4 filing
Jazz Pharmaceuticals plc (JAZZ) · filed Nov 25, 2022
- Accession no.
- 0001765581-22-000126
- Filed
- Nov 25, 2022
- Trade date
- Nov 22, 2022
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions. Open-market sales total $1.05M. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Enright Patrick GCIK 0001253886 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 22, 2022 | Ordinary Shares | SSaleDisposed | −2,905 | $149.18F1 | −$433,367.9 | 21,181 | Direct | |
| Nov 22, 2022 | Ordinary Shares | SSaleDisposed | −2,069 | $149.90F2 | −$310,143.1 | 19,112 | Direct | |
| Nov 22, 2022 | Ordinary Shares | SSaleDisposed | −2,000 | $152.88F3 | −$305,760 | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $148.51 to $149.34. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Referenced by the price of 1 transaction in Table I.
- F2
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $149.76 to $150.06. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Referenced by the price of 1 transaction in Table I.
- F3
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $152.84 to $152.91. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Referenced by the price of 1 transaction in Table I.